CEO Mark Lappe buys 10,040 shares in Inhibrx Biosciences stock

Published on 10/16/2026 at 04:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Four oncology presentations begin October 25, 2026. The 145 percent 12-month return preceded the purchase of Inhibrx Biosciences stock.

Insider buying and clinical dates

CEO Mark Lappe bought 10,040 shares on October 14, 2026.
INBRX-106 produced a 48.3 percent response rate versus 26.5 percent for pembrolizumab alone.
Inhibrx Biosciences stock was last at USD 90.50 on October 15, 2026 at 4:00 p.m. ET.

INBX, US45720N1037, Illustration mit AI erstellt.

Inhibrx Biosciences (US45720N1037) disclosed that CEO Mark Lappe bought 10,040 shares on October 14, 2026, according to StockTitan. The purchase came as the clinical-stage biotech prepared several presentations on its cancer programs.

Why the purchase matters

The October 14 filing covered purchases through two family trusts. The filing reported 2,470 shares bought at a weighted-average USD 84.07, another 2,470 at USD 85.00 and 100 at USD 85.76 in one trust, with matching transactions in a second trust. No Rule 10b5-1 plan was reported in the filing.

Investing.com reported that the stock had delivered a 145 percent return over the preceding twelve months. The same report said the INBRX-106 combination produced a confirmed objective response rate of 48.3 percent, versus 26.5 percent for pembrolizumab alone in previously untreated, PD-L1-positive head and neck cancer patients.

Three insider dates

On September 25, 2026, Lappe's family trust bought 3,324 shares at a weighted-average USD 98.87, according to StockTitan. On September 28, 2026, the same trust bought 3,000 shares at a weighted-average USD 101.70. On October 14, 2026, the combined purchase reached 10,040 shares.

What do the clinical dates add?

The company announced on October 13, 2026, that it would present updated clinical data at four conferences, as Yahoo Finance reported. The sequence gives investors two defined near-term data points: the ESMO Congress on October 25, 2026, and the Musculoskeletal Tumor Society meeting on October 29, 2026. The first presentation covers ordastobart in head and neck cancer, while the second addresses ozekibart in chondrosarcoma.

Nasdaq valuation context

Inhibrx trades on Nasdaq under INBX, according to the company investor page. The latest available Nasdaq quote was USD 90.50 on October 15, 2026 at 4:00 p.m. ET. The stock's 52-week range was USD 28.16 to USD 155.29, and its market capitalization was USD 1.3 billion on that date.

Further presentations are scheduled for November 19 and November 20, 2026, at the Connective Tissue Oncology Society meeting in Seoul, according to Yahoo Finance. Those sessions will cover updated progression-free-survival data and a separate Ewing sarcoma study.